Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 2 clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it provides clinical-stage product, such as LLO-501, cema-cel, ALLO-316, ALLO-329, ALLO-715, and ALLO-605; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors ; Claudin 18.2 for the treatment of gastric and pancreatic cancer; FLT3 for the treatment of acute myeloid leukemia. The company has license and collaboration agreements with Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Allogene Therapeutics Inc.

In a report released yesterday, Robert Burns from H.C. Wainwright reiterated a Buy rating on Allogene Therapeutics, with a price target of $8.00. T...

Allogene Therapeutics (ALLO) Receives a Buy from H.C. Wainwright

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Allogene Therapeutics (ALLO – Research Report), Neur...

Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO), NeurAxis, Inc. (NRXS) and Celcuity (CELC)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Allogene Therapeutics (ALLO – Research Report), Ha...

Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO), Halozyme (HALO) and Progyny (PGNY)

Oppenheimer analyst Matthew Biegler reiterated a Buy rating on Allogene Therapeutics yesterday and set a price target of $7.00. Biegler covers the ...

Current Quarter	$-0.24	Next Quarter	$-0.21
Current Year	$-0.95	Next Year	$-0.88
QoQ Growth	+12.5%	YoY Growth	+7.4%
3Y EPS CAGR	+11.3%	Target Price	$7.56
Consensus	Buy	Upside	+514.6%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ALLO	$1.23	-0.81%	1.59M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ALLO	$1.23	-0.8%	1.59M
3
4
5
6

ALLO

ALLO

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Allogene Therapeutics Inc. Data in Excel

Get Allogene Therapeutics Inc. Data in Excel